NCT07083622Completed
Efficacy of Vitamin C Supplementation on Malondialdehid Levels and Disease Activity in SLE Patients
The Efficacy of Vitamin C Supplementation on Malondialdehid Levels and Disease Activity in Systemic Lupus Erythematosus Patients
Source: ClinicalTrials.gov · Last updated 24 Jul 2025
Brief summary (registry, in English)
The study aimed to evaluate the efficacy of vitamin C supplementation compared to placebo towards malondialdehid levels and disease activity with the MEX-SLEDAI score in Systemic Lupus Erythematosus (SLE) patients. The current study was designed as a single-center double-blind randomized controlled clinical trial. The participants were voluntarily recruited ≥ 18 years old SLE patients, with mild to moderate disease activity and did not consumed vitamin C 1 week prior to the trial study. Participants were randomized into two groups receiving vitamin C supplementation, or placebo. Malondialdehid levels and MEX-SLEDAI score were evaluated at the beginning and at the end of the 8 week trial for analysis.
- Status (registry)
- Completed
- Study type
- Interventional
- Enrollment
- 38 (actual)
- First submitted
- 1 Jul 2025
- Start date
- 1 Sept 2024
- Primary completion date
- 30 Nov 2024
- Lead sponsor
- Universitas Sriwijaya
- Diseases
- Lupus (SLE)
- NCT number
- NCT07083622
What you commit to
- Study type: Interventional
- Participants enrolled: 38
- From 1 Sept 2024 to the primary completion date, 30 Nov 2024
- 1 site in 1 country
- Visits and tests: ask the trial team, the registry does not list them
Built from the registry fields of ClinicalTrials.gov. It describes the study, not your situation.
Who cannot take part
Copied verbatim from ClinicalTrials.gov and grouped by topic. Only the trial team decides who can take part.
Prior treatment
- Patients currently taking vitamin C supplementation within the past 3 days.
- Patients who stop taking the study medication for more than 3 weeks.
Other illness
- Patients with other immune-related disorders, either autoimmune or immunocompromised conditions, such as Human Immunodeficiency Virus (HIV) infection.
- Patients with comorbid diseases.
- Patients with a history of kidney stones.
- Drop-Out Criteria
- Occurrence of severe side effects or worsening of the disease.
Other
- Pregnant or breastfeeding patients.
- Patients diagnosed with severe SLE or those who have achieved remission.
- Patients with hemochromatosis.
- Death before the completion of the study.
- Hospitalization or symptom worsening during the intervention period.
- Loss to follow-up.
Who the study is looking for
- All patients diagnosed with mild to moderate systemic lupus erythematosus (SLE).
- Patients aged over 18 years.
- Willing to participate in the study by signing an informed consent form.
Age in the registry: 18 years to - · Sex: All · Does not accept healthy volunteers
Sites (1)
Sites in registry order. Pick your city on the disease page to sort them by distance.
| Site | City | Country | Site status |
|---|---|---|---|
| Mohammad Hoesin General Hospital Coordinator of this site? Confirm its status | Palembang | Indonesia | Unknown status |
This page is information, not medical advice. Discuss any trial with your doctor.